2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5593 Myelodysplastic neoplasms after radiation therapy only

Maria Julia Montoro Montoro, MD, PhD, Valeria Visconte, PhD2, Pamela Acha, PhD3, Anna Aguilera Romero4, Corinna Strupp5, Marina Díaz-Beyá6, Claudia Haferlach, MD7, Raquel De Paz8, Pablo Prieto Martinez9, Víctor Navarro Garces, MSc10, Akram Abushamma, MD11, Hwei-Fang Tien, MD, PhD12, Carlos Carretero13, Andres Jerez, PhD14, Sandra Castaño-Díez, MD15, Hsin-An Hou16, Alice Du-Puy17, Raul Azibeiro18, Tzu Hua Chen, MD19, Wen-Chien Chou, MD, PhD20, Júlia Mestre21, Bor-Sheng Ko Bor-Sheng Ko22, Esther Alonso23, Luca Lanino, MD24, Jan Philipp Bewersdorf, MD25, Anna Martín Carrizosa Jr, MD26, Pierre Fenaux Sr, MD27, Francesc Bosch, MD28, Maria Diez-Campelo, MD, PhD29, Francesc Sole, PhD30, Amer M. Zeidan, MD31, Helena Pomares Sr, MD, PhD32, Yu-Hung Wang, MD, MSc, PhD33, Torsten Haferlach, MD, PhD34, Ulrich Germing, MD35, Jaroslaw P. Maciejewski, MD, PhD, FACP36, Victoria Reyes37, David Valcarcel, MD, PhD38
1 Vall d’Hebron Institute of Oncology, University Hospital Vall d’Hebron, Barcelona, Spain
2 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
3 Vall d’Hebron Institute of Oncology, University Hospital Vall d’Hebron, Barcelona, Spain
4 Vall d'Hebron Institute of Oncology, Barcelona, Spain
5 University Medical Center Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany
6 Hospital Clinic de Barcelona, Barcelona, Spain
7 MLL, Munich, Germany
8 Hospital Universitario La Paz, Madrid, Spain
9 Hospital Morales Meseguer, Murcia, Spain
10 Vall d'Hebron Institute of Oncology, Barcelona, Spain
11 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
12 National Taiwan University Hospital, Taipei, Taiwan
13 Hospital La Fe, Valencia, Spain
14 Vall d’Hebron Institute of Oncology, University Hospital Vall d’Hebron, Barcelona, Spain
15 Hospital Clinic de Barcelona, Barcelona, Spain
16 National Taiwan University Hospital, Taipei, Taiwan
17 Hôpital Saint-Louis, Universite de Paris, Paris, France
18 Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
19 Hospital Morales Meseguer, Murcia, Spain
20 National Taiwan University Hospital, Taipei, Taiwan
21 Josep Carreras Leukaemia Research Institute, Badalona, Spain
22 National Taiwan University Hospital, Taipei, Taiwan
23 ICO-Hospitalet, Hospital Durán I Reynald. IDIBELL, Badalona, Spain
24 University and Yale Cancer Center, New Haven, Connecticut, United States
25 University and Yale Cancer Center, New Haven, Connecticut, United States
26 Vall d’Hebron Institute of Oncology, University Hospital Vall d’Hebron, Barcelona, Spain
27 Hôpital Saint-Louis, Universite de Paris, Paris, France
28 Vall d’Hebron Institute of Oncology, University Hospital Vall d’Hebron, Barcelona, Spain
29 Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
30 Josep Carreras Leukaemia Research Institute, Badalona, Spain
31 University and Yale Cancer Center, New Haven, Connecticut, United States
32 ICO-Hospitalet, Hospital Durán I Reynald. IDIBELL, Badalona, Spain
33 National Taiwan University Hospital, Taipei, Taiwan
34 MLL, Munich, Germany
35 University Medical Center Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany
36 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
37 Vall d'Hebron Institute of Oncology, University Hospital Vall d’Hebron, Barcelona, Spain
38 Vall d’Hebron Institute of Oncology, University Hospital Vall d’Hebron, Barcelona, Spain

Background & aim: Therapy-related myelodysplastic neoplasms (t-MN) are defined as myeloid neoplasms arising after exposure to cytotoxic chemotherapy (CH) and/or radiation therapy (RT). Current classifications consider these patients under a single disease entity, with important therapeutic implications, including exclusion from many clinical trials. We hypothesized that myelodysplastic neoplasms arising after RT alone (MDS-RT) may differ from classical t-MN. Therefore, we aimed to comprehensively characterize the clinical, genomic, and prognostic features of MDS-RT.

 Methods: We conducted an international, multicenter, retrospective study, including patients diagnosed with MDS arising after RT alone for solid tumors, from 14 international institutions. Patients were classified by WHO 2022 classification. Clinical and molecular data were collected at diagnosis (including NGS of myeloid gene mutations). Risk stratification was performed according to the IPSS-R and IPSS-M. Patients were grouped as lower- or higher-risk using an IPSS-R cutoff of ≤3.5 versus >3.5, and IPSS-M categories of very low/low/moderate-low versus moderate-high/high/very high, respectively. Radiation exposure was characterized by cumulative RT dose (Gy) and the estimated percentage of irradiated bone marrow (BM%), calculated from the skeletal regions included in the RT field according to their age- and sex-specific contribution to total functional BM. Median and maximally selected logrank methods were used to identify RT dose and BM% thresholds associated with inferior outcomes. Associations with acute myeloid leukemia (AML) progression, overall survival (OS) and leukemia-free survival (LFS) were evaluated. Statistical analyses were performed using R.

 Results: A total of 194 MDS patients were included. The median age at diagnosis was 76 years (IQR, 69–85) and 59% (n=115) were male. According to WHO 2022 patients were classified as follows: 50% (n=97) of MDS-LB, 12% (n=23) of MDS-SF3B1; 4% (n=7) of MDS-del(5q), 10% (n=20) of MDS-IB1, 9% (n=19%) of MDS-IB2, 6% (n=11) of MDS-TP53, and 9% (n=17) of CMML. According to risk classification, 70% and 68% were included in the lower-risk IPSS-R and IPSS-M, respectively; while 30% and 32% (n=35) in the higher-risk IPSS-R and IPSS-M, respectively. Notably, consistent with historical cohorts of de novo MDS, complex karyotypes were observed in only 14% (25/171) of cases, while 56% (96/171) presented normal karyotype. NGS analysis was performed in 112 (59%) patients. The median number of mutations per patient was 1 (IQR, 1–2), and 92% harbored ≥1 mutation. The mutational landscape also closely resembled that reported in de novo MDS, with TET2 being the most frequently mutated gene (30%), followed by SRSF2 (17%), and SF3B1 and TP53 (16% each). Of note, TP53 multihit alterations were observed in 44% of TP53-mutated patient.

The most frequent primary solid tumors were prostate (33%, n=64), breast (23%, n=44), and head and neck cancers (9%, n=17). The most common RT techniques were three-dimensional conformal radiation therapy (31%, n=44) and intensity-modulated radiation therapy (21%, n=29). The median cumulative RT dose was 55 Gy (IQR, 40–66), and the median estimated irradiated BM% was 6% (IQR, 2–6). The median interval from completion of RT to MDS diagnosis was 65 months (IQR, 21–183).

Median OS and LFS were 44 months (95% CI, 35–58) and 33 months (95% CI, 23–55), respectively. The cumulative incidence of progression to AML at 48 months was 14% (95% CI, 8–29). No significant differences in OS, LFS, or AML progression were observed according to irradiated BM% or cumulative RT dose. In multivariable analyses including demographic variables, IPSS-R or IPSS-M risk category, cumulative RT dose, and irradiated BM%, only higher-risk classification by IPSS-R or IPSS-M was independently associated with an increased risk of AML progression.

 Conclusions: Our study, the largest cohort of MDS arising after RT alone described to date, demonstrates that, in contrast to previous observations in t-MN, MDS-RT exhibits clinical and biological features, as well as outcomes, comparable to those of de novo MDS. These findings challenge the current classification of MDS-RT as a t-MN, support reconsideration of its placement within current classification systems, and suggest that these patients may be managed according to standard therapeutic approaches for de novo MDS.

Maria Julia Montoro Montoro, MD, PhD: No relevant conflicts of interest to declare.